Halozyme Therapeutics currently has a consensus target price of $53.20, suggesting a potential upside of 23.41%. FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues. . SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies . Shareholder Tools. 3535 General Atomics Ct. San Diego, CA. SIC Code 28,283. Fate Therapeutics , Inc. . Address: 3535 General Atomics Ct Ste 200 San Diego, CA, 92121-1140 United States See other locations Phone: (858) 875-1800 Website: www.fatetherapeutics.com Fate Therapeutics upgraded to outperform from neutral at Wedbush, price target raised to $74 from $71. United States. Fate Therapeutics, Inc is a clinicalstage biopharmaceutical company dedicated to the - development of first-in-class cellular immunotherapies for cancer and immune disorders. Prior to [] we have a process in place the begins with RocketReach and ends with huge contact lists for our sales team..it probably saves Feedtrail about 3 months of work in terms of lead gathering. Share. The past year's Receivables Turnover was at 7.08. SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the 2022 Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 9 . Contact About Us 2022 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 - 12278 Scripps Summit Drive, San Diego, CA 92131 | 866.875.1833 | LEGAL | PRIVACY 38,912 shares . SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will host a conference finance.yahoo.com - June 3 at 11:04 AM. 92121. All Fate Therapeutics Locations. Founded in 2007, Fate Therapeutics is a clinical-stage biopharmaceutical company, that is developing . Fate Therapeutics Inc - FATE stock news. Address. Dive Brief: Fate Therapeutics on Thursday reported new results from two early-stage studies testing two types of experimental leukemia treatments that use natural killer cells, an emerging form of cancer immunotherapy. Discover the latest ERP, HCM, CRM, Procurement software purchases and digital transformation initiatives being undertaken by Fate Therapeutics, Inc. and its business and technology executives Do the numbers hold clues to what lies ahead for the stock? We can divert our attention to . The Company's immunooncology pipeline is comprised . 2022 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 - 12278 Scripps Summit Drive, San Diego, CA 92131 | 866.875.1833 | LEGAL | PRIVACY About Us Our Mission The La Jolla, CA-based start-up founded in November 2007 has recruited an all-star team of scientists, clinicians, executives, and investors who together are pursuing the ultimate . Brand your photos with your logo, and market your events! Get Fate Therapeutics Inc (FATE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. San Diego, CA. The stock's 50 day moving average is $25.26 and its two-hundred day moving average is $36.40. 2022 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 - 12278 Scripps Summit Drive, San Diego, CA 92131 | 866.875.1833 | LEGAL | PRIVACY About Us Our Mission Brooklyn, NY 11219. Analyze Fate Therapeutics Receivables Turnover. Financial Statements. 6201 15th Avenue. The company's pipeline includes various off-the-shelf, iPSC-derived cellular immunotherapies for the treatment of several hematological malignancies and advanced solid tumors. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer question about prospects for Fate Therapeutics ( FATE -0.04%), a stock . San Diego, CA, US (HQ) 3535 General Atomics Ct. San Diego, CA, US. We use live photographers making your event fun with an open-air photo studio. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B . Popular Searches: fate therapeutics inc. 2022 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833 | LEGAL View contact profiles from Fate Therapeutics. Fate Therapeutics is seeking a talented and highly motivated individual to oversee the aseptic cell-based manufacturing operations at Fate. SAN DIEGO, April 22, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or " Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 4, 2022 at 5:00 PM ET . San Diego (HQ), CA. 40 licensing and asset acquisition deals involving ALL drugs during 2014-19. jane.d@fatetherapeutics.com) . Download Library. IND enabling development of FT516: A Natural Killer Cell Immunotherapy for Cancer Derived from a Human Inducible Pluripotent Stem Cell. Brian Powl is Chief Commercial Officer at Fate Therapeutics. FATE Fate Therapeutics Inc Current Report Filing (8-k) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications. Scripps Northridge Center will be renovated for Fate Therapeutics. jane.doe@fatetherapeutics.com) being used 96.0% of the time. American Stock Transfer & Trust Company, LLC. . The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its . Ticker NASDAQ: FATE. Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 christina@sternir.com View Kelly Griffis's business profile as Manager, Clinical Trial at Fate Therapeutics. . Bob Valamehr. Fate reported a loss of 48 cents per share in the first quarter of 2021, wider than the year-ago loss of 44 cents and the Zacks . RSS News Feeds. Find contact's direct phone number, email address, work history, and more. Address. Fate Therapeutics Inc Revenue: $10.00 Million | Employees: 376 | Industry: Biotechnology, Stem Cells, Pharmaceuticals . Posted by MarketBeat News on Jun 17th, 2022. Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 christina@sternir.com. The $1,220m strategic collaboration agreement signed in 2018 between Fate Therapeutics The official website for Fate Therapeutics is www.fatetherapeutics.com . About Fate Therapeutics, Inc. Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive . Losses were -$212.15 million, 22.4% more than in 2020. About Fate Therapeutics, Inc. jdoe@fatetherapeutics.com) and first '.' last_initial (ex. Location of similar companies. Fate Therapeutics is a publicly-traded, clinical-stage, biopharmaceutical company mainly focusing on the development of first-in-class cellular immunotherapies. Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cell. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer . Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Global Acute Lymphoblastic Leukemia (ALL) Market Spotlight 2019 Featuring Fate Therapeutics, Novartis, Ono Pharmaceutical - ResearchAndMarkets.com | Malvern Daily Record. Prior to joining Fate, Mr. Powl most recently served as Senior Vice President, Commercial Development & Marketing at MEI Pharma, Inc., where he led the commercialization efforts of a late-stage small molecule program in B-cell malignancies across marketing, sales, market access and commercial operations. The stock has a market capitalization of $2.59 billion, a PE ratio of -11.03 and a beta of 1.71. Upon withdrawal or completion of the parent interventional study, the study site will contact the subject/healthcare provider/legal guardian annually. Fate Therapeutics Office Locations. Fate Therapeutics has an office in San Diego. Mr. Powl brings to Fate Therapeutics extensive commercial leadership experience in hematologic malignancies . Fate Therapeutics shares last traded at $26.80, with a volume of 2,317,211 shares trading hands. ET by Tonya Garcia. Email Alerts. Fate Therapeutics Receivables Turnover is projected to slightly decrease based on the last few years of reporting. Given Fate Therapeutics' higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than Halozyme Therapeutics. Fate Therapeutics Forward-Looking Statements . San Diego, CA. Fate Therapeutics has a consensus target price of $80.36, suggesting a potential upside of 315.10%. June 30, 2022 16:01 ET | Source: Fate Therapeutics, Inc. SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated . The most common Fate Therapeutics Inc email format is first '.' last (ex. . Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. Reporting Owner Name / Address: Relationships: Director: 10% Owner: Officer: Other: Agarwal Shefali C/O FATE THERAPEUTICS, INC. 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO, CA 92131: X: Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE ) and Century Therapeutics Inc (NASDAQ: IPSC ), an analyst at BofA Securities said in a note on Tuesday.The Biopharma Analyst: Tazeen Ahmad has a Buy rating and . The Company has established a . Fun interactive photo studio with onsite printing at your corporate party, birthday parties, Bar Mitzvahs any event! As an integral part of the Manufacturing Team, this role is responsible for providing leadership and direction in the production of drug products for all phases of . 12278 Scripps Summit Dr. Report incorrect company information. Get the latest stock news for Nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public. Contact Us; Advertisement . Full-Time. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. 2022 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 - 12278 Scripps Summit Drive, San Diego, CA 92131 | 866.875.1833 | LEGAL | PRIVACY About Us Our Mission SUITE 200, 3535 GENERAL ATOMICS COURT. finance.yahoo.com - May 9 at 12:11 PM. Dr. Plavsic brings over 20 years of broad technical excellence in global biopharmaceutical . Printed Materials. Fate Therapeutics (FATE) delivered earnings and revenue surprises of 1.72% and 64.34%, respectively, for the quarter ended September 2021. The company applies an in house iPSC and gene-editing platform to develop T- and natural killer cell therapies targeting blood . Fate Therapeutics (FATE) delivered earnings and revenue surprises of 12.82% and 85.93%, respectively, for the quarter ended March 2022. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. NAICS Code 325414,32541. While some stem cell companies strive to develop neatly packaged products for specific medical niches, and some aim to supply research tools others will use, Fate Therapeutics is planning to do all that and more. Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 christina@sternir.com. Print Page. Total: $4,000,000.00. Fate Therapeutics also holds an exclusive license to other inventions of Dr. Jaenisch relating to iPSC technology including PCT/US2008/004516 with a priority date of April 7, 2007, which describes . Fate Therapeutics, Inc. ( NASDAQ:FATE - Get Rating) shot up 7.3% on Friday . . Partners: Janssen Pharmaceuticals, Ono Pharma, Inscripta. About Fate Therapeutics, Inc. Do the numbers hold clues to what lies ahead for the stock? Fate Therapeutics, Inc. ( NASDAQ:FATE - Get Rating )'s share price shot up 7.3% during trading on Friday . Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications. Phone: 800-937-5449. www.amstock.com. A Scripps Ranch life science lab and office campus has been leased to Fate Therapeutics for its corporate headquarters. You can contact Fate Therapeutics, Inc.'s Board of Directors to provide comments, to report concerns, or to ask a question, at the following address. Get Verified Emails for Fate Therapeutics Inc Employees. You may submit your concern anonymously or confidentially by postal mail. About Fate Therapeutics, Inc. How can I contact Fate Therapeutics' transfer agent? Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. . Fate Therapeutics, Inc.Torrey Pines. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. 92121. 3535 General Atomics Court, Suite 200. Search About Fate Therapeutics, Inc. Relationship of Reporting Person(s) to Issuer . Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 christina@sternir.com . Fate Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference.